Actively Recruiting

Phase 4
Age: 18Years - 70Years
All Genders
NCT06679816

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

Led by Beijing Tiantan Hospital · Updated on 2025-01-14

882

Participants Needed

1

Research Sites

81 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are: • Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency. Participants will: * Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks * Visit the clinic three months after surgery for checkups and tests * Keep a diary of their symptoms

CONDITIONS

Official Title

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 70 years old
  • Diagnosed with a pituitary neuroendocrine tumor suitable for endoscopic transsphenoidal surgery
  • Tumor size is 2 centimeters or larger
  • Intact hypothalamic pituitary adrenal axis before surgery
  • Signed informed consent form by participant or legal representative
Not Eligible

You will not qualify if you...

  • History of Cushing's disease or adrenal insufficiency
  • Receiving emergency or combined hormone therapy
  • History of pituitary stroke
  • Lack of head magnetic resonance imaging

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beijing, Beijing Tiantan Hospital,Capital Medical University

Beijing, Beijing Municipality, China, 100070

Actively Recruiting

Loading map...

Research Team

X

xingchao wang, Phd

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors | DecenTrialz